258 related articles for article (PubMed ID: 28718828)
1. Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.
Bell S; Dean J; Gilks C; Boyd MA; Fitzgerald L; Mutch A; Baker P; Neilsen G; Gartner CE
Int J Environ Res Public Health; 2017 Jul; 14(7):. PubMed ID: 28718828
[TBL] [Abstract][Full Text] [Related]
2. Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners' attitudes.
Bell SK; Mena G; Dean J; Boyd M; Gilks C; Gartner C
Drug Alcohol Depend; 2017 Aug; 177():67-70. PubMed ID: 28577393
[TBL] [Abstract][Full Text] [Related]
3. Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV.
Edwards S; Puljević C; Dean JA; Gilks C; Boyd MA; Baker P; Watts P; Howard C; Gartner CE
AIDS Behav; 2023 Feb; 27(2):618-627. PubMed ID: 35869375
[TBL] [Abstract][Full Text] [Related]
4. A pilot randomised controlled trial of abrupt versus gradual smoking cessation in combination with vaporised nicotine products for people receiving alcohol and other drug treatment.
Skelton E; Lum A; Robinson M; Dunlop A; Guillaumier A; Baker A; Gartner C; Borland R; Clapham M; Bonevski B
Addict Behav; 2022 Aug; 131():107328. PubMed ID: 35405479
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, safety and cost-effectiveness of vaporized nicotine products versus nicotine replacement therapy for tobacco smoking cessation in a low-socioeconomic status Australian population: a study protocol for a randomized controlled trial.
Howard BC; McRobbie H; Petrie D; Barker D; Mendelsohn C; Anderson J; Borland R; Naughton F; Tutka P; Zwar N; Boland VC; Aiken A; Shakeshaft A; Gartner C; Richmond RL; Hall W; Mattick RP; Farrell M; Courtney RJ
Trials; 2022 Sep; 23(1):777. PubMed ID: 36104702
[TBL] [Abstract][Full Text] [Related]
6. Barriers and facilitators to using vaporised nicotine products as smoking cessation aids among people receiving treatment for substance use disorder.
Lum A; Skelton E; Robinson M; Guillaumier A; Wynne O; Gartner C; Borland R; Baker A; Dunlop A; Wilkinson RB; Bonevski B
Addict Behav; 2022 Jan; 124():107097. PubMed ID: 34536632
[TBL] [Abstract][Full Text] [Related]
7. Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?
Giles ML; Gartner C; Boyd MA
AIDS Res Ther; 2018 Dec; 15(1):26. PubMed ID: 30541577
[TBL] [Abstract][Full Text] [Related]
8. Protocol for a randomised pragmatic policy trial of nicotine products for quitting or long-term substitution in smokers.
Fraser D; Borland R; Gartner C
BMC Public Health; 2015 Oct; 15():1026. PubMed ID: 26444980
[TBL] [Abstract][Full Text] [Related]
9. Tobacco harm reduction: the need for new products that can compete with cigarettes.
Fagerström KO; Bridgman K
Addict Behav; 2014 Mar; 39(3):507-11. PubMed ID: 24290207
[TBL] [Abstract][Full Text] [Related]
10. Views and preferences of people living with HIV about smoking, quitting and use of nicotine products.
Edwards S; Fitzgerald L; Mutch A; Dean JA; Ford P; Howard C; Watts P; Gartner C
Int J Drug Policy; 2021 Nov; 97():103349. PubMed ID: 34252787
[TBL] [Abstract][Full Text] [Related]
11. Australian urban Indigenous smokers' perspectives on nicotine products and tobacco harm reduction.
Yuke K; Ford P; Foley W; Mutch A; Fitzgerald L; Gartner C
Drug Alcohol Rev; 2018 Jan; 37(1):87-96. PubMed ID: 28493405
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial Comparing the Effect of Nicotine Versus Placebo Electronic Cigarettes on Smoking Reduction Among Young Adult Smokers.
Tseng TY; Ostroff JS; Campo A; Gerard M; Kirchner T; Rotrosen J; Shelley D
Nicotine Tob Res; 2016 Oct; 18(10):1937-1943. PubMed ID: 26783292
[TBL] [Abstract][Full Text] [Related]
13. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction.
Kozlowski LT; Abrams DB
BMC Public Health; 2016 May; 16():432. PubMed ID: 27221096
[TBL] [Abstract][Full Text] [Related]
14. Electronic cigarettes as a harm reduction strategy among patients with COPD: protocol for an open-label two arm randomized controlled pilot trial.
Stevens ER; Lei L; Cleland CM; Vojjala M; El-Shahawy O; Berger KI; Kirchner TR; Sherman SE
Addict Sci Clin Pract; 2022 Jan; 17(1):2. PubMed ID: 34991693
[TBL] [Abstract][Full Text] [Related]
15. Views and Preferences for Nicotine Products as an Alternative to Smoking: A Focus Group Study of People Living with Mental Disorders.
Meurk C; Ford P; Sharma R; Fitzgerald L; Gartner C
Int J Environ Res Public Health; 2016 Nov; 13(11):. PubMed ID: 27886046
[No Abstract] [Full Text] [Related]
16. E-cigarettes and smoking cessation. Similar efficacy to other nicotine delivery devices, but many uncertainties.
Prescrire Int; 2015 Nov; 24(165):271-6. PubMed ID: 26688909
[TBL] [Abstract][Full Text] [Related]
17. Emerging nicotine delivery products. Implications for public health.
Benowitz NL
Ann Am Thorac Soc; 2014 Feb; 11(2):231-5. PubMed ID: 24575992
[TBL] [Abstract][Full Text] [Related]
18. YouTube as a source of quit smoking information for people living with mental illness.
Sharma R; Lucas M; Ford P; Meurk C; Gartner CE
Tob Control; 2016 Nov; 25(6):634-637. PubMed ID: 26758030
[TBL] [Abstract][Full Text] [Related]
19. [Harm reduction strategy in tobacco control].
Gorini G
Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
[TBL] [Abstract][Full Text] [Related]
20. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy.
Etter JF; Bullen C
Addiction; 2011 Nov; 106(11):2017-28. PubMed ID: 21592253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
